<h4>Background</h4>Emapalumab, an interferon-γ (interferon-gamma)-blocking monoclonal antibody, has emerged as a targeted therapy for refractory hemophagocytic lymphohistiocytosis (HLH). This evidence concerns the gene IFNG and hemophagocytic syndrome.